undamentalytics Newsletter
Sign in

Century Therapeutics, Inc. cash flow statement

In fiscal 2025, Century Therapeutics, Inc.'s operations generated −$104m of cash; it spent $848,000 on capital projects, leaving free cash flow of −$105m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations14−88−110−104
Depreciation and amortisation8131313
Stock-based pay1115137
Capital spending311401
Free cash flow−17−102−110−105
Free cash flow after stock pay−27−117−123−112
Shares issued0100

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IPSC vs XNCRIPSC vs KYMRIPSC vs SPRY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Century Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Century Therapeutics, Inc.